Navigation Links
ACNP: Novel NMDA receptor modulator significantly reduces depression scores within hours
Date:12/6/2012

HOLLYWOOD, FL and EVANSTON, IL, December 6, 2012 -- Naurex Inc., a clinical stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today reported positive results from a Phase IIa clinical trial of its lead antidepressant compound, GLYX-13. GLYX-13 is a novel partial agonist of the NMDA receptor. The Phase Ila results are being presented this week at the 51st Annual Meeting of the American College of Neuropsychopharmacology (ACNP).

The Phase IIa results show that a single administration of GLYX-13 produced statistically significant reductions in depression scores in subjects who had failed treatment with one or more antidepressant agents. The reductions were evident within 24 hours and persisted for an average of seven days. Importantly, the effect size, a measure of the magnitude of the drug's antidepressant efficacy, observed at 24 hours and at seven days after a single administration of GLYX-13, was nearly double the effect size seen with most other antidepressant drugs after 4-6 weeks of repeated dosing.

In the Phase IIa trial, GLYX-13 was well tolerated. Reported side effects were mild to moderate and were consistent with those observed in subjects receiving placebo. Consistent with previous studies, GLYX-13 did not produce any of the schizophrenia-like psychotomimetic effects associated with other drugs that modulate the NMDA receptor.

"These data are an important step in validating Naurex's mission of developing breakthrough therapies for depression and other CNS disorders," said Derek Small, CEO of Naurex. "Our founder discovered a new class of drugs that appeared to have the remarkable antidepressant efficacy of ketamine-like compounds, but without their limiting side effects. These Phase II results suggest that this discovery may translate into measurable health improvements for individuals with depression, which bodes well for the future success of GLYX-13 and the other promising compounds we have generated from this platform."

Other NMDA receptor-modulating agents, such as ketamine, have been shown in several human clinical trials to act very rapidly to alleviate the symptoms of depression and bipolar disorder, but their clinical utility has been hampered by their potential for abuse and behavioral impairment, including schizophrenia-like effects at therapeutic doses.

"We are encouraged by these promising data," noted Ronald M. Burch, MD, PhD, Chief Medical Officer of Naurex. "We have recently begun dosing patients in a GLYX-13 Phase Ilb repeated dose trial, and we are on track to advance our second-generation oral compound, NRX-1074, into clinical trials next year. Preclinical studies show that our novel NMDA modulators may be applicable to a number of CNS disorders, and we look forward to assessing their potential to address major unmet needs in psychiatry and neurology."

The Phase Ila trial was a randomized, double blind, placebo-controlled study of the efficacy and safety of a single dose of intravenous GLYX-13 in subjects who had failed at least one other antidepressant during the current depressive episode. It was conducted at 12 clinical centers in the U.S. Outcome measures included ratings of signs, symptoms and changes in depression scores on standard rating scales for mood and psychiatric disorders. Independent raters from MedAvante, who were blinded to the protocol, administered certain psychiatric assessments for the trial to ensure the quality and objectivity of the screening and rating data. Safety was also assessed.


'/>"/>

Contact: Barbara Lindheim
blindheim@bllbiopartners.com
917-355-9234
BLL Partners, LLC
Source:Eurekalert

Related medicine news :

1. Scripps Florida scientists uncover a novel cooperative effort to stop cancer spread
2. Novel mechanism through which normal stromal cells become cancer-promoting cells identified
3. Novel breast screening technology increases diagnostic accuracy
4. UNC, Vanderbilt discover a new live vaccine approach for SARS and novel coronaviruses
5. Moffitt Cancer Center researchers identify novel metabolic programs driving aggressive brain tumors
6. Novel treatment strategies for epilepsy
7. Taiho Pharmaceutical unveils data on 8 novel anticancer compounds
8. Researchers ID potential patient population who may benefit from novel anti-platelet treatment
9. Undertreatment of common heart condition persists despite rapid adoption of novel therapies
10. Moffitt cancer center researchers find novel predictor for MDS progression risk
11. Novel surgery removes rare tumor, rebuilds face and jaw
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... August 18, 2017 , ... With over 16,000 ... bioidentical hormone replacement therapy and integrative medicine, has become a frontrunner for people ... such as menopause, andropause, thyroid disorder and adrenal insufficiencies. , Founded in ...
(Date:8/18/2017)... ... August 18, 2017 , ... Alcovit, a lime-flavored beverage ... up its marketing efforts with its product now available through Jet.com. , After ... public. The effervescent powdered drink is designed to quickly detox the body thereby avoiding ...
(Date:8/18/2017)... ... 2017 , ... 800response, the leading provider of dynamic call-to-action ... launch of a redesigned corporate website, 800response.com . , Key features ... an enhanced search directory for businesses and advertising agencies to use to ...
(Date:8/18/2017)... ... ... “Dangerous Inheritance”: a mystery about saving the family farm. “Dangerous Inheritance” ... where she was raised on a farm. As Diane wrote this story, she ... friendships and mantra of ‘neighbors helping neighbors’ have always been a large part of ...
(Date:8/18/2017)... ... August 18, 2017 , ... “Beyond Our Imaginations: The Infinite God”: shows the ... Infinite God” is the creation of published author, Mark Lawrence, born in Michigan, the ... “The problem with becoming a greater man of God is that I have to ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... -- Endo International plc (NASDAQ: ENDP ) today ... known U.S. mesh product liability claims and that it ... U.S. claims at reasonable values. Under the agreements, Endo ... of 2017 and continuing through the fourth quarter of ... the Company intends to increase its mesh product liability ...
(Date:8/3/2017)... , Aug. 3, 2017  Opioid addiction and ... driving up healthcare costs and threatening outcomes, were problems ... supply and IVD industry that support them, met this ... market researcher said that drugs of abuse, procalcitonin and ... sessions at the organization,s 69th meeting in ...
(Date:8/2/2017)... Aug. 2, 2017  Life Flight Network and PeaceHealth Oregon ... improves patient care and operational efficiency for patients at hospitals ... , Cottage Grove , and ... PeaceHealth and Life Flight Network work collaboratively to move patients ... or when a time sensitive emergency exists. ...
Breaking Medicine Technology: